CEO total pay
$23,173,052
Robert B. Ford · 2025
Say on pay
Not disclosed
Use Ask for the underlying narrative
CEO pay ratio
Item 402(u)166 to 1
Median employee: $145,528
Compensation committee
CD&ACompensation Committee
Per the latest proxy
Filings indexed: 2 · 2026 · 2025
Executive pay
What did they pay them?
From the Summary Compensation Table. Pay mix and YoY are computed from these rows.
| Executive | Role | TotalYoY | Pay mix | Salary | Stock | Cash incentive | Other |
|---|---|---|---|---|---|---|---|
Robert B. Ford2025 compensation | Chairman of the Board and Chief Executive Officer | $23,173,052↑ 2% | 89% at-risk | $1,500,000 | $8,787,378 | $1,968,750 | $959,798 |
Philip P. Boudreau2025 compensation | Executive Vice President, Finance and Chief Financial Officer | $8,250,640→ 0% | 87% at-risk | $974,231 | $3,045,935 | $1,055,400 | $74,418 |
Lisa D. Earnhardt2025 compensation | Executive Vice President and Group President, Medical Devices | $7,631,875↑ 16% | 85% at-risk | $924,231 | $2,543,989 | $1,283,400 | $178,953 |
Hubert L. Allen2025 compensation | Former Executive Vice President, General Counsel and Secretary | $6,576,450↓ 18% | 80% at-risk | $524,019 | $2,095,392 | $447,500 | $653,224 |
Daniel G. Salvadori2025 compensation | Executive Vice President and Group President, Established Pharmaceuticals and Nutritional Products | $6,252,557↑ 8% | 81% at-risk | $924,231 | $2,238,786 | $388,200 | $212,501 |
Christopher J. Scoggins2025 compensation | Executive Vice President, Diabetes Care | $5,472,142 | 82% at-risk | $859,502 | $1,662,503 | $1,095,300 | $108,443 |
Pay mix: base cash incentive equity other
CD&A excerpt
Compensation discussion & analysis
Opening passage of the loaded filing's CD&A. Use Ask below to query the full text with citations.
Read the full CD&A on SEC.gov ↗
Governance
Policy guardrails
hedging
Hedging
“Hedging”
pledging
prohibited
“Directors and officers are prohibited from holding Abbott stock in a margin account, pledging Abbott stock, or otherwise securing any of their obligations by assigning Abbott stock as collateral.”
clawback
present
“clawback policy.”
change in control
These arrangements are described in greater detail in the “Potential Payments Upon Termination or Change in Control” section of this proxy.
“These arrangements are described in greater detail in the “Potential Payments Upon Termination or Change in Control” section of this proxy.”
compensation consultant
independent
“independent compensation consultant”
compensation committee
Compensation Committee
“The Compensation Committee may recover incentive compensation awarded to a senior executive in the prior three years or reduce future awards.”
Performance markers
Metric facts
revenue
$930
“daysover TargetTargetTargetNot Achieved0.0%Strategic metrics(3)Goal (15% weight): Complete the necessary pricing and capacity expansion metricsper approved plansAchieved17.5%Human capital metricsGoal (10% weight): Meet t…”
ceo pay ratio
166 to 1
“we use for our named executive officers as disclosed in the Summary Compensation Table on page 55 and then added the cost of medical and dental benefits ($16,795) in the calculation of annual total compensation for the m…”
median employee compensation
$145,528
“total compensation for this employee using the same methodology we use for our named executive officers as disclosed in the Summary Compensation Table on page 55 and then added the cost of medical and dental benefits ($1…”
Ask
Anything about ABBOTT LABORATORIES’s 2026 proxy
Answers are grounded in the loaded filing and cite specific artifacts. Bring your own free Google AI Studio key.
Loading the Ask interface…